2CUREX AB (PUBL) Inactive Instrument
2cureX AB (publ) Stock Nasdaq Stockholm
Equities
SE0010468124
Biotechnology & Medical Research
| Sales 2022 | 3.37M 320K | Sales 2023 | 2.95M 280K | Capitalization | 35.38M 3.36M |
|---|---|---|---|---|---|
| Net income 2022 | -29M -2.76M | Net income 2023 | -32M -3.04M | EV / Sales 2022 | 29.3 x |
| Net cash position 2022 | 44.89M 4.27M | Net cash position 2023 | 13.4M 1.27M | EV / Sales 2023 | 7.46 x |
| P/E ratio 2022 |
-4.81
x | P/E ratio 2023 |
-1.09
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Director of Finance/CFO | 48 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Calendar
2024-08-21
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -37.33% | 8.55B | |
| +14.86% | 3.8B | |
| +7.38% | 2.44B | |
| -25.96% | 1.87B | |
| -17.30% | 1.74B | |
| +36.49% | 1.19B | |
| +32.58% | 830M | |
| -7.64% | 711M | |
| -18.37% | 589M |
